Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

M. Ernest Marshall, Michael K. Wolf, E. David Crawford, Sarah Taylor, Brent Blumenstein, Robert Flanigan, Frederick J Meyers, Harry E. Hynes, Bart Barlogie, Mario Eisenberger

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)207-209
Number of pages3
JournalInvestigational New Drugs
Volume11
Issue number2-3
DOIs
StatePublished - Jun 1993

Fingerprint

Echinomycin
Renal Cell Carcinoma
Nausea
Vomiting
Therapeutics
Confidence Intervals

Keywords

  • echinomycin
  • kidney
  • renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Marshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., ... Eisenberger, M. (1993). Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study. Investigational New Drugs, 11(2-3), 207-209. https://doi.org/10.1007/BF00874157

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study. / Marshall, M. Ernest; Wolf, Michael K.; Crawford, E. David; Taylor, Sarah; Blumenstein, Brent; Flanigan, Robert; Meyers, Frederick J; Hynes, Harry E.; Barlogie, Bart; Eisenberger, Mario.

In: Investigational New Drugs, Vol. 11, No. 2-3, 06.1993, p. 207-209.

Research output: Contribution to journalArticle

Marshall, ME, Wolf, MK, Crawford, ED, Taylor, S, Blumenstein, B, Flanigan, R, Meyers, FJ, Hynes, HE, Barlogie, B & Eisenberger, M 1993, 'Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study', Investigational New Drugs, vol. 11, no. 2-3, pp. 207-209. https://doi.org/10.1007/BF00874157
Marshall, M. Ernest ; Wolf, Michael K. ; Crawford, E. David ; Taylor, Sarah ; Blumenstein, Brent ; Flanigan, Robert ; Meyers, Frederick J ; Hynes, Harry E. ; Barlogie, Bart ; Eisenberger, Mario. / Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study. In: Investigational New Drugs. 1993 ; Vol. 11, No. 2-3. pp. 207-209.
@article{14e2072fc9dc455e843a724d47cd40ee,
title = "Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study",
abstract = "Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2{\%} (95{\%} confidence interval, 0-11{\%}). Eighteen patients (38{\%}) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.",
keywords = "echinomycin, kidney, renal cell carcinoma",
author = "Marshall, {M. Ernest} and Wolf, {Michael K.} and Crawford, {E. David} and Sarah Taylor and Brent Blumenstein and Robert Flanigan and Meyers, {Frederick J} and Hynes, {Harry E.} and Bart Barlogie and Mario Eisenberger",
year = "1993",
month = "6",
doi = "10.1007/BF00874157",
language = "English (US)",
volume = "11",
pages = "207--209",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2-3",

}

TY - JOUR

T1 - Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

AU - Marshall, M. Ernest

AU - Wolf, Michael K.

AU - Crawford, E. David

AU - Taylor, Sarah

AU - Blumenstein, Brent

AU - Flanigan, Robert

AU - Meyers, Frederick J

AU - Hynes, Harry E.

AU - Barlogie, Bart

AU - Eisenberger, Mario

PY - 1993/6

Y1 - 1993/6

N2 - Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

AB - Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

KW - echinomycin

KW - kidney

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027244912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027244912&partnerID=8YFLogxK

U2 - 10.1007/BF00874157

DO - 10.1007/BF00874157

M3 - Article

VL - 11

SP - 207

EP - 209

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2-3

ER -